Mediocre Vaccine Could Make Pandemic Worse, Non-Profit Group Tells US FDA
Executive Summary
Ahead of the vaccine advisory committee, requests to FDA range from public health groups opposing emergency use authorizations to industry seeking labeling guidance on EUA products.
You may also be interested in...
NIH Considering Trial of COVID-19 Vaccines and Asymptomatic Transmission
US FDA’s Peter Marks says transmission prevention is one of three key missing data points he’d like from Pfizer and BioNTech’s newly authorized vaccine. Another concern is how the vaccine will work is the virus “drifts.”
Republican Lawmaker Takes Unusual Step Of Attacking FDA Salaries Over Abortion Pill Decisions
A move to cut senior FDA positions including CDER Director through the appropriations process is rare and almost certain to fail, but experts say the attempt is indicative of an environment that seems to be encouraging these personal amendments.
Intarcia’s Implantable GLP-1 Gets Unanimous No Vote But Lots Of New Trial Design Advice
A US FDA advisory panel feels there could be a place for Intarcia’s exenatide drug-device combo – if the company is willing to put in the work.